Director Henry Brem joins Galectin (GALT) board and reports zero share ownership

Rhea-AI Filing Summary

Galectin Therapeutics Inc. director Henry Brem filed an initial ownership report on Form 3 showing no common stock holdings. The filing indicates that, as of the reporting date, he is a director of the company but does not beneficially own any shares of common stock directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Brem Henry

Role Director

Type	Security	Shares	Price	Value
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 0 shares (Direct)

Footnotes (1)

Understanding Insider Trading Forms →

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Brem Henry

(Last) (First) (Middle)

4960 PEACHTREE INDUSTRIAL BLVD

SUITE 240

(Street)

NORCROSS GA 30071

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
03/12/2026

3. Issuer Name and Ticker or Trading Symbol
GALECTIN THERAPEUTICS INC [ GALT ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	0	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	Jack W. Callicutt, by power of attorney	03/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What does Henry Brem's Form 3 filing mean for GALECTIN THERAPEUTICS INC (GALT)?

The Form 3 shows Henry Brem has become a director of Galectin Therapeutics Inc. It also reports that he holds zero shares of common stock, providing a baseline for any future changes in his ownership reported on later Forms 4 or 5.

Did Henry Brem buy or sell any GALT shares in this Form 3 filing?

No, this Form 3 does not report any purchases or sales of GALT shares. It is an initial ownership statement and shows that Henry Brem beneficially owns zero shares of common stock as of the reported date.

How many GALECTIN THERAPEUTICS INC (GALT) shares does Henry Brem own after this Form 3?

The Form 3 reports that Henry Brem beneficially owns zero shares of Galectin Therapeutics Inc. common stock. This establishes his starting ownership position as a director, against which any future reported transactions can be compared.

What role does Henry Brem have at GALECTIN THERAPEUTICS INC (GALT) in this Form 3?

The filing identifies Henry Brem as a director of Galectin Therapeutics Inc. Form 3 is required when someone becomes a reporting insider, and this document records his position and confirms he has no direct common stock ownership at that time.

Does Henry Brem have any derivative or option positions in GALT according to this Form 3?

The insider data provided does not show any derivative or option positions for Henry Brem. The derivative section is empty, and the only reported security is common stock with total holdings of zero shares following the reported date.